Metrion Biosciences look forward to attending, presenting posters and exhibiting at the Virtual Safety Pharmacology Society (SPS) Annual Meeting to be held from 14th to 17th September 2020. Metrion will be located at Booth # 400 in the exhibits hall for the duration of the virtual event. Our collaborative poster with Nanion Technologies will be [...]
Introducing Damian Bell: as a new member of the team at Metrion we are using an abridged version of an interview by Artem Kondratskyi for ionchannellibrary.com. A big thank you to Artem for sharing this interview and a quick plug for his website – we highly recommend it as an excellent resource for anyone [...]
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines Part of the US FDA’s Comprehensive in vitro Proarrythmia Assay (CiPA) Initiative Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today [...]
Metrion Biosciences and Nanion Technologies look forward to hosting their first collaborative webinar on Tuesday 28th April entitled: Validation and optimization of automated patch clamp voltage-gated Ca2+ channel assays. The webinar will feature Metrion's CSO Dr. Marc Rogers. Marc will outline the development, optimisation and validation of a range of voltage-gated Ca2+ channel assays on [...]
Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research Initial twelve month collaboration successfully identifies hit compounds and progresses into hit-to-lead optimisation phase Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical [...]
Thank you to the ELRIG Committee and to BioStrata for allowing us to share the below content on our website. The British Pharmacological Society (BPS) ran a special symposium at the ELRIG Drug Discovery 2019 conference yesterday, focused on the importance of targeting ion channels for drug discovery. As a unique platform to foster the [...]
Dr Edward Humphries will be presenting at the Sophion Japanese User meeting on Friday 11th October to be held at the Knowledge Capital Conference Rooms at the Grand Front, Osaka. Edd's talk is entitled: "Advancing Cardiac Safety Screening on the QPatch" Edd will be at the User meeting all day and will be available to [...]
Metrion Biosciences' CSO Dr Marc Rogers will be presenting a drug discovery focused talk at the Pain and Migraine Therapeutics Summit in Washington DC on 23rd to 24th September 2019. Marc will also be available during both days of the conference to discuss Metrion's range of ion channel focused drug discovery services. If you would [...]
Metrion Biosciences' Senior Scientist Dr Edward Humphries will be attending and presenting a talk at the Sophion EU User meeting to be held on Thursday 5th and Friday 6th September 2019 in Copenhagen. The title of Edd's presentation is: "Recent drug discovery applications run on QPatch in CRO collaborative mode" Edd will also be available [...]
Overview The Metrion Biosciences team have recently produced a second application note in collaboration with Sophion Bioscience, describing the use of a ∆KPQ LQT3 mutant to create and validate a Nav1.5 (Late) cardiac safety assay on QPatch 48. Herein, we aim to provide a more reliable and accurate Nav1.5(Late) assay, which removes the requirement [...]
